Related Experiment Video
Updated: Dec 7, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Long-term outcomes of elderly patients receiving continuous flow left ventricular support
Nicolas A Brozzi1, Renzo O Cifuentes1, Isabela C Saba1
1Department of Surgery, Division of Thoracic Transplantation and Mechanical Circulatory Support, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Insights
Elderly patients with advanced heart failure show comparable outcomes and low complication rates when treated with continuous-flow left ventricular assist devices. This therapy offers a safe alternative to heart transplantation for older adults.
Area of Science:
- Cardiology
- Medical Devices
- Geriatrics
Background:
- Heart failure affects over 6 million Americans, with 80% of patients older than 65.
- Heart transplantation, the gold standard, is less accessible to elderly patients (only 18.5% are 65+).
- Continuous-flow left ventricular assist devices (CF-LVADs) provide a safe and effective treatment for advanced heart failure.
Purpose of the Study:
- To evaluate the long-term outcomes of elderly patients receiving CF-LVADs.
- To compare the safety and efficacy of CF-LVADs in older adults versus younger patients.
Main Methods:
- Retrospective analysis of elderly patients who received CF-LVADs.
- Characterization of long-term clinical outcomes and complication rates.
Main Results:
- Elderly patients demonstrated comparable operative results to younger counterparts.
- Low rates of complications were observed up to 6 years of CF-LVAD support.
- Outcomes in elderly patients were comparable to those in younger patient groups.
Conclusions:
- CF-LVADs are a safe and effective alternative for elderly patients with advanced heart failure.
- This therapy provides a viable option for patients less likely to receive a heart transplant.
- Long-term support with CF-LVADs is feasible and beneficial for the aging heart failure population.
Background:
Heart failure is an epidemic affecting over 6 million people in the United States. Eighty percent of all heart failure patients are older than 65 years of age. Heart transplant is the gold standard treatment for patients suffering advanced heart failure, but only 18.5% of patients receiving heart transplant in the United States are 65 years of age or older. Continuous-flow left ventricular assist devices are a safe and effective therapy for patients with advanced heart failure, and can be used to bridge patients to a heart transplant or to support patients long-term as destination therapy.
Material And Methods:
We sought to characterize long-term outcomes of elderly patients receiving continuous-flow left ventricular support in our program.
Conclusion:
Elderly patients with advanced heart failure presented comparable operative results to those of younger patients. The rate of complications up to 6 years of support was low, and comparable to those of younger patients. An effective and safe alternative for patients whom are less likely to receive heart transplantation.
More Related Videos
03:40Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure II: Pathophysiology